Get started
Author

Mirjeta Berisha

Observed name: Berisha, Mirjeta
ORCID: 0000-0001-5625-7858
Observed ORCID: 0000-0001-5625-7858
OpenAlex ID: A5041014183
N-glycosylation controls inflammatory licensing-triggered PD-L1 upregulation in human mesenchymal stromal cells
2020 · Vivien Strauch, Domenica Saul, et al. · Stem Cells · 19
Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
2022 · Tobias R. Haage, Alexey Surov, et al. · HemaSphere · 14
Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients
2024 · Vanja Zeremski, Louisa Adolph, et al. · European Journal Of Haematology · 8
PDF
Chlorhexidine gluconate‐coated gel pad dressings for prevention of central venous catheter‐related bloodstream infections in patients with hematologic diseases or autologous stem cell transplantation: A registry‐based matched‐pair analysis
2023 · Daniel Teschner, Mirjeta Berisha, et al. · European Journal Of Haematology · 5
Lautropia mirabilis sepsis in immunodeficiency: first report and genomic features
2024 · Svea Genseke, Mirjeta Berisha, et al. · Infection · 4
Unraveling the immune microenvironment in primary CNS lymphoma
2026 · Sven Lorenzen, Vanja Zeremski, et al. · Biomarker Research · 3
PDF
Hypogammaglobulinemia and Anti-CD20 Therapy-Induced Acute Thrombocytopenia: Perhaps More than a Coincidence?
2024 · Tobias Ronny Haage, Vanja Zeremski, et al. · Oncology Research and Treatment · 3
PDF
Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma
2024 · Rebecca Wurm-Kuczera, Khouloud Kouidri, et al. · Blood · 2
Tigecycline as salvage treatment of febrile neutropenia in patients with haematological malignancies—a retrospective single-centre analysis of 200 cases
2023 · Daniel Geßner, Mirjeta Berisha, et al. · Annals of Hematology · 2
PDF
Evidence for early, clinically silent medial temporal lobe inflammation after CAR-T cell therapy
2026 · Marwa Al Dubai, Mahima Verginia Rebello, et al. · European Journal of Cancer · 1
PDF
Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma
2025 · Thomas Oellerich, Rebecca Wurm-Kuczera, et al. · Blood · 1
Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease
2026 · Mirjeta Berisha, Denise Walther, et al. · HemaSphere
Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease
2026 · Berisha, Mirjeta, Walther, Denise, et al. · Fraunhofer-Publica (Fraunhofer-Gesellschaft)
Evidence for early, clinically silent medial temporal lobe inflammation after CAR-T cell therapy
2026 · Al Dubai, Marwa, Rebello, Mahima Verginia, et al. · Fraunhofer-Publica (Fraunhofer-Gesellschaft)
Works count: 15
Citation count: 62
H-index: 4
I10-index: 2
Year
Topic
Type